Vatten Pharma

Vatten Pharma

روّاد الأعمال

Alfredo Bittar

Alfredo Bittar

Executive Director

Alfredo Bittar is a Executive Director at Vatten Pharma.
K 0 $
K 0 $

  • Vatten Pharma has joined FasterCapital's portfolio.
  • We help startups in building their product, increasing sales, entering new markets, finding investors, and writing and preparing their documents.
  • Entrepreneurs can join our main programs; Tech Cofounder, Grow your Startup, Idea to Product, or Raise Capital.

Idea

Vatten Pharma is building a next-generation pharmaceutical platform focused on transforming cannabinoid and phytotherapeutic treatments through advanced nanotechnology. The company’s core idea is to overcome the absorption, safety, and cost barriers of existing CBD products by delivering pharmaceutical-grade, water-soluble formulations optimized for central nervous system (CNS) and chronic pain indications. By combining cutting-edge formulation science with a diversified product portfolio and a LATAM-focused expansion strategy, Vatten aims to redefine how cannabinoid-based therapies are prescribed, consumed, and scaled across regulated medical markets.

Challenge

Vatten Pharma is addressing the fundamental limitations of traditional oil-based CBD therapies, which suffer from low bioavailability, high patient burden, and poor treatment adherence. Conventional CBD oils achieve only 6–10% absorption due to first-pass liver metabolism, resulting in inconsistent dosing, delayed therapeutic onset, and significant waste of active ingredients. This inefficiency forces patients to consume higher doses, increasing monthly treatment costs and limiting long-term adherence. Additionally, oily taste, gastrointestinal discomfort, and imprecise dosing mechanisms create significant usability challenges, particularly for elderly patients and children.

Solution

Vatten Pharma is delivering a nano water-soluble CBD technology that bypasses first-pass metabolism and achieves near-complete absorption, making it up to 10x more potent than traditional oil-based products. Recognized by the body as water, the formulation enables rapid onset of action, consistent dosing, and significantly improved therapeutic efficacy at lower doses. The solution is tasteless, easy to administer by mixing with any liquid, and eliminates gastrointestinal discomfort, driving better patient adherence. Higher potency translates directly into lower cost per effective dose, improving affordability while meeting pharmaceutical-grade safety and quality standards required by physicians and regulators.


Are you interested in investing in Vatten Pharma?


Let us know!

برامجنا

تأمين رأس المال

نساعد الشركات الناشئة على جمع التمويل من خلال التواصل مع المصتثمرين المناسبين وتقديم دعم وخدمات متكاملة

تمويل مشاريع ضخمة

حلول تمويل واسعة النطاق للشركات الناشئة والشركات ذات إمكانيات النمو الكبيرة.

الشريك التقني

نصبح الشريك المؤسس التقني لشركتك، ونتولى تطوير المنتج ونقدم خبرات تقنية استراتيجية.

حسّن مبيعاتك

قم بتوسيع أعمالك من خلال استراتيجيات وموارد وشراكات تركز على النمو.

من فكرة إلى منتج

حوّل أفكارك المبتكرة إلى منتجات مكتملة وجاهزة للسوق بمساعدتنا المتخصصة.

تمويل مشاريع الإعمار

حلول تمويل شاملة مصممة خصيصًا للشركات الناشئة والشركات العاملة في قطاع العقارات.

فرانتشايز للشركات

استكشف فرص الامتياز التجاري وقم بتطوير أعمالك ضمن نموذج عمل مُثبت.

حقوق الملكية الفكرية

احمِ حقوق الملكية الفكرية الخاصة بك مع توجيه خبراء في براءات الاختراع والعلامات التجارية وحقوق النشر والمزيد.

بدء شركة في الإمارات

نحن نساعدك في تأسيس عملك في الإمارات من خلال حلول مخصصة، دعم قانوني، واستراتيجيات دخول إلى السوق.

أخبار Vatten Pharma (1)

Vatten Pharma & FasterCapital Equitypilot Partnership Accelerates CBD Nanotech to Latin American Medical Markets
03 Jan 2026

Vatten Pharma & FasterCapital Equitypilot Partnership Accelerates CBD Nanotech to Latin American Medical Markets

SÃO PAULO, Brazil & Dubai, UAE - Jan 03, 2026 

Vatten Pharma and FasterCapital today announced a strategic partnership through FasterCapital’s Equitypilot program to accelerate commercialization of VATTEN’s water‑soluble CBD nanotechnology across Latin America. The collaboration pairs FasterCapital’s global acceleration, capital and network with VATTEN’s pharmaceutical R&D, regulatory roadmap and clinical ambitions.

Market opportunity & problem statement

The global medicinal CBD market is rapidly expanding, with Latin America underpenetrated due to quality, dosing variability and physician reluctance. In Brazil and broader LATAM, patients pay premium prices for inconsistent, artisanal products and prescribers (70% reported information gaps) cite contamination and dosing concerns. VATTEN addresses this white space: a pharmaceutical-grade, hydrosoluble CBD offering improved bioavailability and medical credibility where demand, regulatory clarity and import growth converge.

Startup solution & differentiation

VATTEN PHARMA’s Ultra CBD uses nanotech to deliver up to 10x greater absorption versus conventional oils, enabling lower doses, improved safety and consistent pharmacology. Built on pharmaceutical manufacturing controls, purity certification and a scientific evidence program, VATTEN targets prescriber trust through physician education, clinical studies and partnerships with centers of excellence. Initial go-to-market leverages U.S. inventory and phased Brazilian manufacturing  with product lines spanning medical, veterinary and cosmetic segments and a prioritized launch in clinical channels.

FasterCapital partnership value

Through Equitypilot, FasterCapital provides structured seed capital, mentorship, go‑to‑market support, regulatory strategy, investor introductions and access to commercialization partners. FasterCapital’s selective criteria prioritize startups with defensible IP, regulatory pathways and scalable models; VATTEN passed these filters based on clinical focus, technology novelty and LATAM market fit. The partnership targets key milestones: Phase‑2 manufacturing set‑up (2025), Phase‑3 clinical evidence and Brazilian registration (2026) and expanded regional launches.

Executive quotes

“[VATTEN PHARMA] represents the kind of deep‑tech, clinically focused company we seek to accelerate strong science, clear regulatory pathway and high market need,” said Hesham Zreik, founding investor and advisor at FasterCapital. “Our Equitypilot resources will compress time to market and de‑risk early commercialization.”

“Physicians and patients need reliable, pharmaceutical‑grade CBD options backed by evidence. FasterCapital’s capital and network let us scale manufacturing, advance clinical trials and build the educational programs prescribers demand,” said Alfredo Bittar CEO of VATTEN PHARMA. “This partnership validates our approach and accelerates access to safer, more effective treatments.”

Growth trajectory & near-term roadmap

Near term VATTEN will finalize Brazilian manufacturing plans, deploy a specialized medical sales force, and initiate Phase‑3 clinical studies while expanding U.S. and EU online sales. Funding rounds guided by FasterCapital will support R&D, regulatory filings, and market rollouts to Mexico and LATAM. Long‑term, VATTEN aims to be a market leader in pharmaceutical CBD formulations and to broaden its pipeline into adjacent CNS and pain indications.

About VATTEN PHARMA

VATTEN PHARMA is a Latin American pharmaceutical company specializing in technology-driven plant-derived medicines. Pioneering water‑soluble CBD nanotechnology and clinical research, VATTEN focuses on physician adoption, manufacturing quality and evidence-based treatments across human, veterinary and cosmetic lines.

About FasterCapital

FasterCapital is a global venture builder and online incubator dedicated to co-funding and co-founding innovative startups. Established in 2014, we are now #1 venture builder in terms of number of startups that we have helped, money invested and money raised. It supports startups worldwide through various programs, including funding assistance, business development, and technical support. The Equitypilot program is designed to help early-stage startups build scalable solutions with mentorship, strategic guidance, and network support.

أرسل بريد إلكتروني!